The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study

Overview

Journal Trop Med Infect Dis

Specialty Infectious Diseases

Date 2022 Mar 24

PMID 35324598

Authors

Ganghee Chae

Aram Choi

Soyeoun Lim

Sooneun Park

Seungjun Lee

Youngick Ahn

Jinhyoung Kim

Seungwon Ra

Yangjin Jegal

Jongjoon Ahn

Eunji Park

Jaebum Jun

Woonjung Kwon

Taehoon Lee

Affiliations

Soon will be listed here.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determine the effectiveness of the combined use of remdesivir and regdanvimab in patients with severe COVID-19.

Methods: From March to early May 2021, 124 patients with severe COVID-19 were admitted to Ulsan University Hospital (Ulsan, Korea) and received oxygen therapy and remdesivir. Among them, 25 were also administered regdanvimab before remdesivir. We retrospectively compared the clinical outcomes between the remdesivir alone group [ = 99 (79.8%)] and the regdanvimab/remdesivir group [ = 25 (20.2%)].

Results: The oxygen-free days on day 28 (primary outcome) were significantly higher in the regdanvimab/remdesivir group [mean ± SD: 19.36 ± 7.87 vs. 22.72 ± 3.66, = 0.003]. The oxygen-free days was also independently associated with use of regdanvimab in the multivariate analysis, after adjusting for initial pulse oximetric saturation (SpO)/fraction of inspired oxygen (FiO) ratio (severity index). Further, in the regdanvimab/remdesivir group, the lowest SpO/FiO ratio during treatment was significantly higher (mean ± SD: 237.05 ± 89.68 vs. 295.63 ± 72.74, = 0.003), and the Kaplan-Meier estimates of oxygen supplementation days in surviving patients (on day 28) were significantly shorter [mean ± SD: 8.24 ± 7.43 vs. 5.28 ± 3.66, = 0.024].

Conclusions: In patients with severe COVID-19, clinical outcomes can be improved by administering regdanvimab, in addition to remdesivir.

Citing Articles

Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis.

Kee Y, Park H, Yoon S, Yu S, Ko E, Cho A Kidney Res Clin Pract. 2024; 43(1):111-121.

PMID: 38268125 PMC: 10846986. DOI: 10.23876/j.krcp.23.137.

COVID-19: Current Status and Future Prospects.

Leggat P, Frean J, Blumberg L Trop Med Infect Dis. 2023; 8(2).

PMID: 36828510 PMC: 9966066. DOI: 10.3390/tropicalmed8020094.

References

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Rice T, Wheeler A, Bernard G, Hayden D, Schoenfeld D, Ware L . Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007; 132(2):410-7. DOI: 10.1378/chest.07-0617. View

Taylor P, Adams A, Hufford M, de la Torre I, Winthrop K, Gottlieb R . Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21(6):382-393. PMC: 8054133. DOI: 10.1038/s41577-021-00542-x. View

Kim J, Jang Y, Hong J, Jung J, Park J, Streinu-Cercel A . Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild.... Clin Ther. 2021; 43(10):1706-1727. PMC: 8380488. DOI: 10.1016/j.clinthera.2021.08.009. View

Borghesi A, Maroldi R . COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. Radiol Med. 2020; 125(5):509-513. PMC: 7194501. DOI: 10.1007/s11547-020-01200-3. View

Simonis F, Serpa Neto A, Binnekade J, Braber A, Bruin K, Determann R . Effect of a Low vs Intermediate Tidal Volume Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical Trial. JAMA. 2018; 320(18):1872-1880. PMC: 6248136. DOI: 10.1001/jama.2018.14280. View

Lee T, McDonald E, Butler-Laporte G, Harrison L, Cheng M, Brophy J . Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. Int J Infect Dis. 2021; 104:671-676. PMC: 7849442. DOI: 10.1016/j.ijid.2021.01.065. View

Olivas-Martinez A, Cardenas-Fragoso J, Jimenez J, Lozano-Cruz O, Ortiz-Brizuela E, Tovar-Mendez V . In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation. PLoS One. 2021; 16(2):e0245772. PMC: 7857625. DOI: 10.1371/journal.pone.0245772. View

Kim C, Ryu D, Lee J, Kim Y, Seo J, Kim Y . A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021; 12(1):288. PMC: 7803729. DOI: 10.1038/s41467-020-20602-5. View

10.

Ryu D, Kang B, Noh H, Woo S, Lee M, Nuijten P . The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2. Biochem Biophys Res Commun. 2021; 578:91-96. PMC: 8436435. DOI: 10.1016/j.bbrc.2021.09.023. View

11.

Wang Z, Wang Z . Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak. BMC Infect Dis. 2021; 21(1):113. PMC: 7829622. DOI: 10.1186/s12879-021-05814-4. View

12.

Park S . Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020; 63(4):119-124. PMC: 7170784. DOI: 10.3345/cep.2020.00493. View

13.

Choi K, Hong H, Kim E . The Association between Mortality and the Oxygen Saturation and Fraction of Inhaled Oxygen in Patients Requiring Oxygen Therapy due to COVID-19-Associated Pneumonia. Tuberc Respir Dis (Seoul). 2020; 84(2):125-133. PMC: 8010412. DOI: 10.4046/trd.2020.0126. View

14.

Ulrich R, Troxel A, Carmody E, Eapen J, Backer M, DeHovitz J . Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. Open Forum Infect Dis. 2020; 7(10):ofaa446. PMC: 7543602. DOI: 10.1093/ofid/ofaa446. View

15.

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View

16.

Lee J, Lee J, Ko J, Hyun M, Kim H, Cho S . Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease. Front Immunol. 2021; 12:772320. PMC: 8657590. DOI: 10.3389/fimmu.2021.772320. View

17.

Lee S, Lee S, Lee J, Kim K, Lee S, Hwang S . Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study. Int Immunopharmacol. 2022; 106:108570. PMC: 8813598. DOI: 10.1016/j.intimp.2022.108570. View

18.

Kim S, Kim J, Huh K, Choi W, Kim Y, Joo E . Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Recommendations for Anti-SARS-CoV-2 Monoclonal Antibody Treatment of Patients with COVID-19. Infect Chemother. 2021; 53(2):395-403. PMC: 8258293. DOI: 10.3947/ic.2021.0304. View

19.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

20.

Sheikh A, McMenamin J, Taylor B, Robertson C . SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293):2461-2462. PMC: 8201647. DOI: 10.1016/S0140-6736(21)01358-1. View